Standard BioTools Inc. (LAB)

NASDAQ: LAB · IEX Real-Time Price · USD
2.150
-0.110 (-4.87%)
At close: Jun 14, 2024, 4:00 PM
2.220
+0.070 (3.26%)
After-hours: Jun 14, 2024, 7:20 PM EDT
-4.87%
Market Cap 823.56M
Revenue (ttm) 126.76M
Net Income (ttm) -135.98M
Shares Out 383.05M
EPS (ttm) -1.01
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,754,845
Open 2.240
Previous Close 2.260
Day's Range 2.150 - 2.245
52-Week Range 1.570 - 3.160
Beta 1.66
Analysts Strong Buy
Price Target 3.58 (+66.51%)
Earnings Date Aug 6, 2024

About LAB

Standard BioTools Inc., together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology inst... [Read more]

Sector Healthcare
IPO Date Feb 10, 2011
Employees 534
Stock Exchange NASDAQ
Ticker Symbol LAB
Full Company Profile

Financial Performance

In 2023, LAB's revenue was $106.34 million, an increase of 8.57% compared to the previous year's $97.95 million. Losses were -$74.66 million, -60.73% less than in 2022.

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for LAB stock is "Strong Buy." The 12-month stock price forecast is $3.58, which is an increase of 66.51% from the latest price.

Price Target
$3.58
(66.51% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Standard BioTools Purchases the Carterra® LSA-XT System to Accelerate Data Delivery and Provide Greater Validation to SomaScan Customers

SOUTH SAN FRANCISCO, Calif and SALT LAKE CITY, May 28, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB) today announced that it has purchased the LSAXT system from Carterra®, a leading pro...

17 days ago - GlobeNewsWire

Standard BioTools to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (“Standard BioTools”) (Nasdaq:LAB) today announced that its management team will participate in the following inves...

23 days ago - GlobeNewsWire

Standard BioTools Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., May 20, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (“Standard BioTools”) (Nasdaq:LAB) today announced that the Human Capital Committee of its Board of Directors, whic...

25 days ago - GlobeNewsWire

Standard BioTools Reports First Quarter 2024 Financial Results

SOUTH SAN FRANCISCO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (“Standard BioTools” or the “Company”) (Nasdaq: LAB) today announced financial results for the first quarter ended ...

5 weeks ago - GlobeNewsWire

Standard BioTools Announces Operational Restructuring Plan to Drive Long-Term Profitable Growth

SOUTH SAN FRANCISCO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (“Standard BioTools” or the “Company”) (Nasdaq: LAB) today announced that it has initiated a restructuring plan t...

7 weeks ago - GlobeNewsWire

Standard BioTools Introduces New High-Throughput Multiplexed Whole Slide Imaging Modalities Set to Redefine the boundaries of Tissue Imaging

New advancements, including automation, aim to fast-forward spatial biology New advancements, including automation, aim to fast-forward spatial biology

2 months ago - GlobeNewsWire

Standard BioTools Announces Multi-Year Strategic Engagement with Bristol Myers Squibb for Use of the SomaScan® Platform for Translational Medicine Research

SOUTH SAN FRANCISCO, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health™ – today an...

2 months ago - GlobeNewsWire

Standard BioTools Announces Exchange of All Outstanding Series B Convertible Preferred Stock for Common Stock

SOUTH SAN FRANCISCO, Calif., March 18, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (“Standard BioTools” or the “Company”) (Nasdaq: LAB) today announced that it has exchanged all outstanding shares...

3 months ago - GlobeNewsWire

Standard BioTools Reports Fourth Quarter and Full Year 2023 Financial Results

SOUTH SAN FRANCISCO, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (“Standard BioTools” or the “Company”) (Nasdaq: LAB) today announced financial results for the fourth quarter and ...

3 months ago - GlobeNewsWire

Standard BioTools Announces Conference Call and Webcast for Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024

SOUTH SAN FRANCISCO, Calif., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health™ – today ann...

4 months ago - GlobeNewsWire

Standard BioTools and Navignostics Announce Collaboration Agreement to Advance Imaging Capabilities in Personalized Medicine

Increasing access to Imaging Mass Cytometry in pharmaceutical and clinical research settings Increasing access to Imaging Mass Cytometry in pharmaceutical and clinical research settings

4 months ago - GlobeNewsWire

Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2023 Revenue

Achieving scale with pro forma full year 2023 revenue of approximately $192 million Achieving scale with pro forma full year 2023 revenue of approximately $192 million

5 months ago - GlobeNewsWire

Standard BioTools Completes Merger with SomaLogic, Creating a Diversified and Scaled Leader in Life Sciences Tools

Establishes Leading Platform of Complementary Multi-omic Technologies with Enhanced Scale and Commercial Reach; Strengthened Balance Sheet to Self-Fund Future Growth Initiatives Establishes Leading Pl...

5 months ago - GlobeNewsWire

Standard BioTools Stockholders Approve Merger with SomaLogic

SOUTH SAN FRANCISCO, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq: LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health, today anno...

5 months ago - GlobeNewsWire

SomaLogic Stockholders Vote to Approve Standard BioTools Transaction at Special Meeting

Stockholder Approval Represents Key Milestone Toward Completion of Standard BioTools Transaction Combination Will Create a Diversified Leader in Life Sciences Tools BOULDER, Colo. , Jan. 4, 2024 /PRNe...

5 months ago - PRNewsWire

Boston Millennia Partners Intends to Vote Against Proposed Merger of SomaLogic With Standard BioTools

BOSTON--(BUSINESS WIRE)--Boston Millennia Partners (“Boston Millennia”), a significant shareholder of SomaLogic (the “Company”) (Nasdaq: SLGC) today announced that it intends to vote against the Compa...

5 months ago - Business Wire

Madryn Asset Management Highlights Increasing Public Shareholder Opposition to Value-Destructive SomaLogic Merger and Calls on Company to Make Additional Disclosures

NEW YORK--(BUSINESS WIRE)--Madryn Asset Management, LP (collectively with its affiliates, “Madryn” or “we”), a holder of approximately 4.2% of the outstanding common stock of SomaLogic, Inc. (“SomaLog...

6 months ago - Business Wire

Glass Lewis Recommends Standard BioTools Stockholders Vote “FOR” All Proposals Relating to Proposed Merger with SomaLogic

SOUTH SAN FRANCISCO, Calif., Dec. 29, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq: LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health, today anno...

6 months ago - GlobeNewsWire

Dr. Larry Gold and Dr. Jason Cleveland Issue Open Letter to SomaLogic Stockholders Opposing SomaLogic's Proposed Merger with Standard BioTools

BOULDER, Colo. , Dec. 28, 2023 /PRNewswire/ -- Dr. Larry Gold, the founder of SomaLogic, Inc. ("SomaLogic" or the "Company") (Nasdaq: SLGC) and Dr. Jason Cleveland, SomaLogic's current Chief Technolog...

6 months ago - PRNewsWire

Tikvah Management Announces Intention to Vote against Somalogic's Proposed Merger with Standard BioTools

CHARLOTTE, N.C.--(BUSINESS WIRE)--Tikvah Management (“Tikvah”), a significant shareholder of Somalogic (the “Company”) (Nasdaq: SLGC) with voting rights for 5.9 million shares, or 3.1% of the outstand...

6 months ago - Business Wire

Madryn Asset Management Reiterates Alternative Path to SomaLogic's Value-Destructive Proposed Merger with Standard BioTools

NEW YORK--(BUSINESS WIRE)--Madryn Asset Management, LP (“Madryn Asset Management” and, collectively with its affiliates, “Madryn” or “we”), a holder of approximately 4.2% of the outstanding common sto...

6 months ago - Business Wire

ISS Recommends Standard BioTools Stockholders Vote “FOR” All Proposals Relating to Proposed Merger with SomaLogic

SOUTH SAN FRANCISCO, Calif., Dec. 22, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq: LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health - today ann...

6 months ago - GlobeNewsWire

Madryn Asset Management Highlights Newly-Disclosed Conflicts of Interest Related to Proposed SomaLogic Merger with Standard BioTools

NEW YORK--(BUSINESS WIRE)--Madryn Asset Management, LP (“Madryn Asset Management” and, collectively with its affiliates, “Madryn”), a holder of approximately 4.2% of the outstanding common stock of So...

6 months ago - Business Wire

Skye Fund III Issues Letter Regarding Opposition to SomaLogic's Proposed Merger with Standard BioTools

Believes that the Proposed Merger Grossly Undervalues SomaLogic and Ignores its Revolutionary Products, Considerable Cash Position, and Strong Balance Sheet Iterates that SomaLogic can Thrive as a Sta...

6 months ago - GlobeNewsWire

Madryn Asset Management Issues Presentation Detailing Why SomaLogic Shareholders Should Vote “AGAINST” the Value-Destructive and Deeply Flawed Proposed Merger with Standard BioTools

NEW YORK--(BUSINESS WIRE)--Madryn Asset Management, LP (“Madryn Asset Management” and, collectively with its affiliates, “Madryn”), a holder of approximately 4.2% of the outstanding common stock of So...

6 months ago - Business Wire